secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2026-06-01T11:00:24+00:00
Accession:  0001493152-26-026519
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available
--------------------------------------------------------------------------------

- ANDA submitted to FDA for generic version of an undisclosed anticoagulant drug product.
- IQVIA reports branded product sales of $26 billion for twelve months ending March 2026.
- No generic product currently on market; brand has unexpired patents and exclusivity in FDA Orange Book.
- FDA approval and commercialization subject to successful filing, approval, and addressing patents.
- Elite expands pipeline into high-value anticoagulant market; no timeline for launch provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/0001493152-26-026519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-026519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer